We are pioneering a new class of medicine we call endobody vaccines that are fully synthetic and train the body to safely and efficiently treat and prevent neurological disease.
We are not afraid to be brave and tackle the seemingly impossible. We are committed to transforming the lives of all patients and families affected by Alzheimer’s, Parkinson’s, CTE and other neurological diseases.
We envision a world where neurodegenerative diseases are prophylactically eradicated.
By The Numbers
80 years ago, it was polio. Today, our epidemic is Alzheimer’s.
CHANCE YOU WILL HAVE ALZHEIMER’S
IF OVER 85 YEARS OLD
ANNUAL COST TO THE WORLD
Just as science brought us a vaccine against polio and virtually eradicated the disease worldwide, we are working to develop vaccines to treat and ultimately prevent Alzheimer’s and other neurological diseases.
We aren’t your average vaccine company.
We have built a robust translational platform to rapidly design and develop targeted immunotherapeutics based on the industry’s leading endobody vaccine technology. After two decades of research and over 3 billion doses commercialized on other indications, we are now developing the world’s most advanced active vaccine against Alzheimer’s.
November 14, 2018 -
United Neuroscience is developing a novel class of vaccines that target aberrant proteins implicated in neurodegenerative diseases. Now it has strong preclinical evidence showing that one of its vaccines could hold promise in Parkinson’s disease.Read More
November 13, 2018 -
UNS today announced the presentation of pre-clinical evidence for UB-312, a Parkinson's disease vaccine candidate, at the Parkinson's UK Research Conference. The presentations highlights the potential of the UNS's technology to address brain disorders across a variety of therapeutic areas, including Alzheimer's disease and Parkinson's disease.Read More